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Abstract
Background: Regulatory t cells (treg) and dendritic
cells (Dc) play an important role in tumor immunity
and immune escape. However, their interplay and the
effects of  anti-cancer therapy on the human immune
system are largely unknown.
Methods: For Dc generation, cD14+ monocytes were
enriched by immunomagnetic selection from peripher-
al blood of  advanced head and neck squamous cell
carcinoma (Hnscc) patients and differentiated into
immature Dc using GM-scF and Il-4. Dc matura-
tion was induced by addition of  tnFα. the frequency
of  cD4+cD25highFoXP3+ treg in Hnscc patients
was analyzed before and after radio-chemotherapy
(Rct) by four-color flow cytometry.
Results: In Hnscc patients, the frequency of  treg
(0.33 ± 0.06%) was significantly (p = 0.001) increased
compared to healthy controls (0.11 ± 0.02%), whereas
Rct had variable effects on the treg frequency induc-
ing its increase in some patients and decrease in oth-
ers. after six days in culture, monocytes of  all patients
had differentiated into immature Dc. However, Dc
maturation indicated by cD83 up-regulation (70.7 ±
5.5%) was successful only in a subgroup of  patients
and correlated well with lower frequencies of  periph-
eral blood treg in those patients.
Conclusion: the frequency of  regulatory t cells is ele-
vated in Hnscc patients and may be modulated by
Rct. Monocyte-derived Dc in Hnscc patients show
a maturation deficiency ex vivo. those preliminary
data may have an impact on multimodality clinical tri-
als integrating cellular immune modulation in patients
with advanced Hnscc.
Key words: head and neck cancer, dendritic cell, vacci-
nation, regulatory t cell, chemotherapy
Abbreviations: 
5-Fu 5-fluorouracil
Dc Dendritic cells
FoXP3 Forkhead box P3
GM-csF Granulocyte macrophage colony-stimulating 
factor
Hnscc Head and neck squamous cell cancer
PBMc Peripheral blood mononuclear cells
Rct Radio-chemotherapy
tGFb transforming growth factor beta
tnFα tumor necrosis factor alpha
treg Regulatory t cells
IntRoDuctIon
Radical surgery and various radio-chemotherapy
(Rct) regimens represent the current therapy stan-
dards for patients with head and neck squamous cell
cancer (Hnscc). However, local recurrence and dis-
tant metastasis are still the major limiting factors for
improving survival rates [1]. aside from anti-EGFR
antibody therapy and targeted therapy with tyrosine ki-
nase inhibitors, newer therapeutic approaches have
been focused on dendritic cell (Dc)-based im-
munotherapy [2]. Dc are unique antigen-presenting
cells characterized by their potent t-cell stimulatory
activity and therefore, they are preferentially utilized in
cancer vaccines [3]. Immature Dc capture antigens in
peripheral tissues and migrate to secondary lymphoid
organs after danger signal-induced maturation. there,
Dc present the captured antigens to specific t cells.
For cancer vaccination, Dc are loaded with specific
tumor antigen or mRna and administered to cancer
patients in hope of  stimulating an anti-tumor t-cell re-
sponse [4]. a number of  human vaccination studies
utilizing Dc have been recently published for various
tumor entities, however, Dc-based vaccinations for
therapy of  human Hnscc are rare [5].
the production of  Dc-based vaccines requires
techniques for a large-scale ex vivo generation of  clini-
cal-grade Dc, and several methods for Dc generation
have been established [3]. Dc can be directly isolated
from the peripheral blood, which may be hampered by
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the low number and functional abnormalities of  Dc
in cancer patients [6]. currently, Dc culture for thera-
py utilizes monocytes separated from leukapheresis
products [7]. For this purpose, in patients with cancer,
monocytes have to be collected before Rct as their
number drops rapidly after Rct. Whether Hnscc pa-
tients at this disease stage have functionally normal
monocytes which can be used to generate Dc vaccines
is currently unknown.
to date, Dc-based vaccines for cancer have not yet
fulfilled their promise, as clinical benefits are only
rarely reported in therapeutic vaccination trials, such
as in prostate cancer [8]. this lack of  clinical benefits
might be partly due to the strong immunosuppressive
influence of  regulatory t cells (treg) in cancer pa-
tients with advanced malignancies.
cD4+cD25highFoXP3+ treg play an important role
in various human diseases including the development
of  allergy [9], host-versus-graft-reaction in transplan-
tation [10], and autoimmune diseases [11]. all are as-
sociated with a decrease in treg numbers. In contrast,
in cancer patients, treg are frequently elevated and can
inhibit t-cells, Dc, natural killer t-cells and even B-
cells, thereby probably contributing to tumor immune
escape [12]. the potential influence of  Rct on treg
has been addressed in several recent studies. In breast
cancer, FoXP3+ cells infiltrating the tumor were de-
creased in frequency after neoadjuvant chemotherapy,
and a reduced treg infiltration correlated with im-
proved responses [13]. also in breast cancer,
trastuzumab therapy in combination with chemothera-
py resulted in a decrease of  treg in peripheral blood
[14]. In end-stage cancer patients with various tumor
types, a low dose of  cyclosphosphamide caused a se-
lective depletion of  treg in peripheral blood [15]. For
Hnscc, a study by strauss et al. showed that onco-
logic therapy induced a significant increase in the fre-
quency and suppressor function of  treg in the periph-
eral circulation. surprisingly, Hnscc patients had a
higher frequency of  treg after successful therapy
compared to patients with active untreated disease
[16].
the present study focuses on Dc generation and
the alteration of  cD4+cD25highFoXP3+ treg during
Rct in Hnscc patients. understanding the frequen-
cy and function of  treg and Dc is necessary to effec-
tively orchestrate the various regimens of  surgery,
Rct and anti-cancer immune therapy.
MatERIal anD MEtHoDs
Study design
Patients of  all age groups with the diagnosis of  Hn-
scc (t1-4) donated blood for the generation of  Dc
(mean age: 63.1yrs, 0 female, 9 male) and treg quan-
tification (mean age: 58.8yrs, 2 female, 11 male) after
informed consent. Experiments were approved by the
local ethics committee. two patients suffered from re-
current tumor disease, and all patients received prima-
ry or adjuvant Rct with curative intent (table 1). Dc
generation was performed prior to Rct, and the fre-
quency of  treg was determined before as well as one
week (6.8 ± 2 days) after chemotherapy. three differ-
ent protocols of  chemotherapy were distinguished: (a)
single dose of  cisplatin (n = 3), (b) one course of  5-
fluorouracil and cisplatin ± cetuximab (n = 4), and (c)
one course of  mitomycin c and cisplatin (n = 6). the
control group consisted of  10 healthy volunteers.
Generation of  dendritic cells
Dc were generated following a protocol adapted from
Zhou et al. [17, 18]. cD14+ monocytes were im-
munoselected from peripheral blood mononuclear
cells (PBMc) using ls separation columns on a Vari-
oMacs (Miltenyi Biotec, Bergisch Gladbach, Ger-
many). Enriched cD14+ monocytes were cultured in
24-well plates (Greiner, nürtingen, Germany) at
1 x 1 06 cells/ml and 2ml/well of  serum-free cell-
GroDc medium (cellgenix, Freiburg, Germany) sup-
plemented with 1,000 u/ml GM-csF (leukine,
Berlex, Richmond, ca) and 1,000 u/ml Il-4 (cell-
genix). after 3 and 6 days, half  of  the medium was re-
placed by fresh medium containing cytokines. to in-
duce Dc maturation, 1,000 u/ml tnFα (cellgenix),
GM-csF and Il-4 were added on day 6, and cultures
were continued for 3 days. Monocyte purity was deter-
mined by flow cytometry, using cD45-FItc (BD 
Biosciences, Heidelberg, Germany) and cD14-PE 
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Table 1. Patients characteristics.
Dendritic cell culture Treg frequency
number and gender 9 (9 male, 0 female) 13 (11 male, 2 female)
Mean age (range) 63.1 yrs (47 – 72) 58.8 yrs (47 – 73)
tumor site: larynx 2 3
oral cavity 3 6
Pharynx 3 4
Maxillary sinus 1 0
tumor stage: t1 1 1
t2 1 2
t3 4 3
t4 3 6
Recurrent disease 0 2
surgical treatment 2 3
(Beckman-coulter, krefeld, Germany) monoclonal
antibodies. to monitor Dc differentiation and matura-
tion, the frequencies of  cD14+cD83neg monocytes,
cD14negcD83neg immature Dc and cD14negcD83+
mature Dc were determined by flow cytometry using
cD14-PE and cD83-FItc (Beckman-coulter) mono-
clonal antibodies.
Flow cytometric determination of  Treg frequencies
Venous blood (1ml) was collected in heparinized
tubes and erythrocyte lysis was performed with 14ml
ammonium chloride solution (nH4cl) for 10min at
4°c. after washing cells twice with PBs, cells were
permeabilized with 1ml cytofix solution (BD Bio-
sciences) for 15min at 4 °c, washed twice with
Permwash solution (BD Biosciences) and stained in
Permwash solution with cD25-PEcy5, cD4-PEcy7,
cD8-aPc (all BD Biosciences) and FoXP3-FItc
(eBioscience, Frankfurt, Germany) monoclonal anti-
bodies for 20min at 4 °c. Finally, cells were washed in
4ml PBs and fixed with 100 µl 4% para-formalde-
hyde (EMs, Hatfield, Pa) prior to analysis on a Facs
canto flow cytometer using DIVa software (BD Bio-
sciences). treg were identified as cD4+cD25high-
FoXP3+ lymphocytes by sequential gating (Fig. 1),
and frequencies of  treg are shown as percent (%) of
cD4+ lymphocytes. absolute numbers were calculated
from frequencies and cell counts determined on a
blood cell analyzer.
Statistical analysis
Data are presented as geometric means ± standard er-
ror of  means, and statistical significance was evaluated
using the student’s t-test.
REsults
Frequency of  regulator y T cells
the frequency of  treg in Hnscc patients prior and
after radio-chemotherapy as well as in the control
group was determined by flow cytometry. treg were
identified as cD4+cD25highFoxP3+ cells within the
lymphocyte population (Fig. 1). the mean frequency
of  cD4+cD25highFoXP3+ treg measured by flow cy-
tometry (n = 13) was significantly increased (p =
0.001) in Hnscc patients prior to Rct (0.33 ± 0.6%)
compared to healthy controls (0.11 ± 0.2%). Rct had
diverse effects with an average treg frequency of  0.36
± 0.09% after Rct (Fig. 2). seven patients showed an
average increase of  +0.28 ± 0.1% in treg frequency
after Rct while the other six patients showed an aver-
age decrease of  -0.21 ± 0.1%.
the frequency of  treg was further determined in
subgroups of  patients according to their chemothera-
py protocol. Whether patients were treated with cis-
platin (n = 3), 5-fluorouracil and cisplatin ± cetuximab
(n = 4), or mitomycin c and cisplatin (n = 6), no uni-
form alteration of  treg frequencies was observed in
any of  these subgroups (Fig. 3). We also determined
the absolute numbers of  lymphocytes, treg and cD4+
t cells before and after Rct as significant variations
in Hnscc patients have been reported [19]. In Hn-
scc patients, the absolute number of  treg decreased
from 11.6 ± 3/μl before Rct to 7.1 ± 3/μl after
Rct. correspondingly, the absolute number of  cD4+
t cells in Hnscc patients decreased from 3,437 ±
364/μl before Rct to 1,960 ± 367/μl after Rct.
the mean number of  leukocytes measured by whole
blood count was 8,800 ± 0.7/µl before Rct and
5,600 ± 0.6/µl after Rct.
Dendritic cell generation
to analyze the functionality of  monocytes in Hnscc
patients, peripheral blood monocytes were differenti-
ated into immature Dc in the presence of  GM-csF
and Il-4 before maturation was induced by the addi-
tion of  tnFα. Differentiation and maturation were
monitored by determining the expression of  the
monocyte marker cD14 and the marker for mature
Dc, cD83, on the cell surface [20]. Immunomagnetic
monocyte enrichment (n = 9) resulted in a high purity
of  cD14+ cells (85.3 ± 3.2%). after six days of
monocyte culture with GM-csF and Il-4, cells
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Fig. 1. strategy for flow cytometric determination of treg
frequencies. treg frequencies in peripheral blood of patients
and controls were determined by flow cytometry. lympho-
cytes (a) were identified based on their forward (Fsc) and
side scatter characteristic (ssc). Within the lymphocyte popu-
lation, cD4+cD8neg cells were gated (B) and the subpopula-
tion of cD25highFoXP3+ cells quantitated in a dotplot
showing cD25 versus FoXP3 expression (c).
showed a loss of  cD14 marker (16.3 ± 9.0%). cD83
expression, was detectable only on a small fraction of
cells (1.5 ± 0.4%), which confirms that the cultured
monocytes had acquired the cD14negcD83neg pheno-
type of  immature Dc (Fig. 4).
Following maturation of  the cells with tnFα,
cD14 expression was almost absent (0.8 ± 0.2%),
whereas cD83 was up-regulated (38.8 ± 10.6%
cD83+ cells), indicating maturation of  Dc. However,
the ability of  Dc to mature in Hnscc patients (n=6)
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Fig. 2. treg frequencies in peripheral blood of
Hnscc patients. treg frequencies of Hnscc
patients before and after Rct (n=13) or from
healthy individuals (n = 10) were determined as
illustrated in Figure 1. Results are shown as per-
centages of cD4+cD25highFoXP3+ treg of
cD4+ lymphocytes and displayed in quartiles of
0, 25, 75 and 100. Horizontal bars indicate geo-
metric mean values.
Fig. 3. the frequency of treg before
and after radio-chemo therapy in indi-
vidual Hnscc patients. treg frequen-
cies before (black bars) and after ra-
dio-chemotherapy (grey bars) of indi-
vidual patients receiving three differ-
ent Rct regimens were determined.
the mean frequency of treg in the
control group is shown in the last col-
umn. Patients showing an increase in
treg frequency after Rct are indicat-
ed (*).
Fig. 4. successive generation of immature and mature dendritic cells from monocytes. Monocytes (day 0) were cultured for 6
days in the presence of GM-csF and Il-4 to induce Dc differentiation, followed by a three day culture period in the presence
of GM-csF, Il-4 and tnFα to induce Dc maturation. Monocyte purity was determined by cD45/cD14 staining (day 0). the
frequency of cD14negcD83neg immature Dc, and cD14negcD83+ mature Dc was determined after 6 and 9 days of culture by
flow cytometry. Quadrants were set according to isotype controls.
appeared to negatively correlate with the frequency of
cD4+cD25highFoXP3+ treg before Rct, with a
trend towards significance (Fig. 5). Patients with a treg
frequency below 0.4% of  cD4+ t cells in the periph-
eral blood showed an increased ability of  Dc matura-
tion measured by cD83 expression (70.3 ± 5.5%)
compared to patients with a treg frequency above
0.4% of  cD4+ t cells, in which cells maintained an
immature phenotype. (20.8 ± 10.5% cD83+ cells).
DIscussIon
tumor induced immunosuppression is a well known
phenomenon in cancer patients, for which changes in
the treg compartment may play a central role [21]. In
the present study, it was documented, that the fre-
quency of  cD4+cD25highFoXP3+ treg in peripheral
blood of  Hnscc patients was significantly increased
compared to healthy controls, suggesting an active
mechanism of  tumor-induced immune escape. this
finding is in accordance with a previous study in Hn-
scc [16] and similar changes have also been reported
for other types of  cancer [12].
Rct has been reported to preferentially deplete
cD4+ t cells in Hnscc patients [19]. analyzing the
effects of  Rct on the treg population, we observed
that in 7/13 patients treg frequencies within cD4+ t
cells increased, whereas 6/13 patients showed a de-
crease in treg frequencies after Rct. Presumably, not
all chemotherapeutic agents have the same effect on
treg frequency, and t cell subsets may be affected dif-
ferently by Rct [22]. studies with a higher number of
patients receiving the same drug regimen could pro-
vide a more definite result. of  note, a lack of  a dis-
tinct phenotypic marker for human treg makes com-
parison of  data obtained by different investigators 
difficult. Most commonly, treg are defined as
cD4+cD25highFoXP3+, but also the presence of
cD39,  and the absence of  cD127 and cD49d have
been used to define treg [23].
the results presented here suggest that there might
be an association between the treg frequency and ab-
normalities in Dc maturation. In Hnscc patients
with a high frequency of  treg in peripheral blood,
monocytes failed to develop to mature Dc ex vivo as
evident by the lack of  cD83 up-regulation. Hnscc
patients with a low frequency of  treg show a normal
ability of  Dc maturation as compared to normal
donors who had 65 ± 6.8% cD83+ cells after tnFα -
induced Dc maturation [18]. Whether such effects are
long lasting or whether there is normalization when
treg are depleted, is currently unknown.
the defective Dc maturation of  monocytes ob-
tained from cancer patients possibly reflects tumor-in-
duced suppression, and tnFα used as the only matu-
ration signal may not be sufficient to overcome this
suppression. several factors that negatively influence
Dc maturation in vitro are described in the literature
including Il-10 and tGFß production by regulatory t
cells [24] or vascular endothelial growth factor pro-
duced by human cancer cells [25]. Both mechanisms, a
direct effect mediated by tumor cells or a tumor-in-
duced effect mediated by treg, could cause the de-
creased Dc maturation in Hnscc patients. In anoth-
er study, high thrombocyte counts in blood samples
were found to interfere with Dc development [26],
but thrombocyte counts were in a normal range in 
all participants of  this study (data not shown). also,
neither the patients’ age nor their level of  alcohol and
nicotine consumption gave an explanation for the 
deficiency in Dc maturation of  certain patients (data
not shown). nevertheless, it should be stressed, 
that monocytes of  all patients differentiated normally
to immature Dc upon culture with GM-csF and 
Il-4, thus, only maturation of  Dc appears to be 
affected.
aiming for an increase in survival rates, future ther-
apy of  Hnscc patients will likely focus on the com-
bination of  surgery, Rct and immunotherapy. In or-
der to determine an optimal and feasible timing of  the
various therapeutic modalities, the understanding of
depletion and recovery of  immuno-relevant cell popu-
lations is essential. therefore, longitudinal studies of
cell frequencies, including treg but also myeloid sup-
pressor cells and tH-17 cells are warranted, all of
which may be differently affected by Rct. Having in
mind that treg are highly immunosuppressive, the ap-
plication of  Dc-based anticancer vaccination would
be most effective when frequencies of  treg are low
and those of  cD4+ and cD8+ lymphocytes are com-
paratively high. Whether this point of  time can be
reached before, during or after Rct needs to be deter-
mined. It will also be important to identify regimens
of  Rct that are most effective for elimination of  im-
munosuppressive treg and functional normalization
of  Dc, as well as subgroups of  patients who will espe-
cially benefit from a supportive anticancer vaccination
therapy. as the combination of  Rct and im-
munotherapy is hypothesized to have an additive ef-
fect in cancer patients, this strategy may provide for
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Fig. 5. association of Dc maturation and treg frequency in
the peripheral blood of Hnscc patients. the frequency of
mature Dc (cD14negcD83+) after 9 days of differentiation
and maturation culture is plotted against the frequency of
cD4+cD25highFoXP3+ treg in the blood of Hnscc pa-
tients prior to Rct (n = 6). treg frequencies are shown as
percent (%) of cD4+ lymphocytes.
the opportunity to employ Rct in a more concerted
manner [27, 28].
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